Delving into the Latest Updates on Var2 Pharmaceutical with Synapse

Overview

Tags

Urogenital Diseases

Skin and Musculoskeletal Diseases

Neoplasms

Biological products

Diagnostic radiopharmaceuticals

Radionuclide Drug Conjugates (RDC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	2
Neoplasms	2
Nervous System Diseases	2

Top 5 Drug Type	Count

Radionuclide Drug Conjugates (RDC)	1
Diagnostic radiopharmaceuticals	1
Biological products	1

Top 5 Target	Count

GAGs(glycosaminogycans)	1

VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues.
VAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.

Start Date01 Nov 2024

Sponsor / Collaborator

Var2 Pharmaceutical

[+1]

100 Clinical Results associated with Var2 Pharmaceutical

Login to view more data

0 Patents (Medical) associated with Var2 Pharmaceutical

Login to view more data

1

Literatures (Medical) associated with Var2 Pharmaceutical

Scientific ReportsQ3 · CROSS-FIELD

Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells

Q3 · CROSS-FIELD

ArticleOA

Author: Adomat, Hans ; Dagil, Robert ; Al Nakouzi, Nader ; Gustavsson, Tobias ; Ghaidi, Fariba ; Nelepcu, Irina ; Choudhary, Swati ; Oo, Htoo Zarni ; Truong, Sarah ; Sorensen, Poul H ; Wang, Chris Kedong ; Tahiry, Zakir ; Zhao, Sarah ; Hui, Desmond ; Daugaard, Mads ; Esfandnia, Shaghayegh ; Salanti, Ali

AbstractProteoglycans are proteins that are modified with glycosaminoglycan chains. Chondroitin sulfate proteoglycans (CSPGs) are currently being exploited as targets for drug-delivery in various cancer indications, however basic knowledge on how CSPGs are internalized in tumor cells is lacking. In this study we took advantage of a recombinant CSPG-binding lectin VAR2CSA (rVAR2) to track internalization and cell fate of CSPGs in tumor cells. We found that rVAR2 is internalized into cancer cells via multiple internalization mechanisms after initial docking on cell surface CSPGs. Regardless of the internalization pathway used, CSPG-bound rVAR2 was trafficked to the early endosomes in an energy-dependent manner but not further transported to the lysosomal compartment. Instead, internalized CSPG-bound rVAR2 proteins were secreted with exosomes to the extracellular environment in a strictly chondroitin sulfate-dependent manner. In summary, our work describes the cell fate of rVAR2 proteins in tumor cells after initial binding to CSPGs, which can be further used to inform development of rVAR2-drug conjugates and other therapeutics targeting CSPGs.

100 Deals associated with Var2 Pharmaceutical

Login to view more data

100 Translational Medicine associated with Var2 Pharmaceutical

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

Login to view more data